Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells
October 24th, 2019
11.6K views
This article describes a method to generate functional tumor antigen-specific induced pluripotent stem cell-derived CD8αβ+ single positive T cells using OP9/DLL1 co-culture system.
Overview
This article describes a method to generate functional tumor antigen-specific induced pluripotent stem cell-derived CD8αβ + single positive T cells using an OP9/DLL1 co-culture system. This technique is significant for in vitro T cell generation and has implications for regenerative medicine and cell-based therapies.
Key Study Components
Area of Science
- Stem Cell Biology
- Immunology
- Cell Therapy
Background
- Induced pluripotent stem cells (iPSCs) can differentiate into various cell types.
- CD8αβ + T cells play a crucial role in the immune response against tumors.
- Co-culture systems are essential for developing functional immune cells from stem cells.
- OP9/DLL1 co-culture provides a supportive environment for T cell differentiation.
Purpose of Study
- To establish a reliable method for generating tumor antigen-specific T cells from iPSCs.
- To enhance the understanding of T cell development in vitro.
- To provide a foundation for future applications in cell-based therapies.
Methods Used
- Co-culture of human iPSCs with OP9-Delta-1 cells.
- Use of ROCK inhibitor to promote cell survival during culture.
- Sequential media changes to support cell growth and differentiation.
- Harvesting and processing of hematopoietic progenitor cells.
Main Results
- Successful generation of CD8αβ + single positive T cells from iPSCs.
- Characterization of differentiated cells showed expected phenotypic markers.
- Demonstrated the adaptability of the method for other lymphocyte types.
- Provided a detailed protocol for reproducibility in research settings.
Conclusions
- The OP9/DLL1 co-culture system is effective for generating functional T cells.
- This method can be utilized for advancing cell-based therapies.
- Future studies can explore the potential of this approach in clinical applications.
Frequently Asked Questions
What are induced pluripotent stem cells?
Induced pluripotent stem cells (iPSCs) are reprogrammed somatic cells that can differentiate into various cell types.
Why is the OP9/DLL1 co-culture system used?
The OP9/DLL1 co-culture system provides a supportive environment for the differentiation of stem cells into T cells.
What role does ROCK inhibitor play in the culture?
ROCK inhibitor enhances cell survival and prevents differentiation during the initial stages of culture.
Can this method be adapted for other cell types?
Yes, the method can be adapted for generating other lymphocyte types, such as NK cells.
What are the implications of this research?
This research has significant implications for regenerative medicine and the development of cell-based therapies for cancer treatment.
Executive Industry Relevance
Generating tumor antigen-specific T cells from human iPSCs enables scalable production of rejuvenated, antigen-specific immune cells for oncology research and cell therapy development. This approach addresses limitations of T cell exhaustion and senescence during expansion, supporting predictive confidence in early immunotherapy pipelines. The method positions iPSC-derived T cells as a renewable resource for translational and preclinical immuno-oncology programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of tumor antigen-specific T cell function in controlled in vitro systems.
- Supports mechanistic de-risking by preserving TCR specificity through reprogramming and redifferentiation.
- Facilitates functional target validation for immuno-oncology assets.
Screening & Assay Development
- Provides a standardized source of antigen-specific T cells for reproducible assay development.
- Enables quantitative assessment of T cell activation and cytokine secretion in response to defined antigens.
- Supports high-throughput screening of immunomodulatory compounds using functional readouts.
Translational & Preclinical Research
- Aligns with disease-relevant models by generating T cells with preserved tumor antigen specificity.
- Enables continuity from discovery to preclinical validation of cell-based immunotherapies.
- Supports risk-adjusted advancement decisions by providing functional, rejuvenated T cells for in vitro and in vivo studies.
Pipeline & Workflow Integration
This method integrates into the immuno-oncology discovery continuum, from early target validation through preclinical evaluation of cell-based therapies.
- Discovery Biology: Supports hypothesis testing of antigen-specific T cell responses and pathway analysis.
- Screening: Delivers reproducible, quantitative outputs for compound and antigen screening platforms.
- Analytics: Enables measurement of cytokine secretion and antigen specificity via ELISpot and flow cytometry.
- Translational Research: Provides a renewable source of functional T cells for bridging in vitro and in vivo studies.
- Enterprise Reuse: Establishes a platform for scalable, repeatable generation of antigen-specific T cells across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in T cell-based immunotherapy research.
- Operational Value: Standardizes T cell generation and enables reproducible, scalable workflows.
- Strategic Value: Improves go/no-go decisions and reduces late-stage biological risk in immuno-oncology portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of cell-based therapeutic candidates.
Implementation Considerations
- Requires expertise in iPSC culture, differentiation, and immunological assays.
- Demands access to OP9-Delta-1 co-culture systems and flow cytometry or ELISpot infrastructure.
- Necessitates rigorous standardization of cell culture conditions and passage timing.
- Adaptable to multiple human cell sources, including hematopoietic and embryonic stem cells.
- Dependent on effective CD4 magnetic bead enrichment to ensure purity and functionality of T cell populations.
Biopharma FAQs
Why does null hypothesis testing matter for ELISpot antigen specificity?
Null hypothesis testing in ELISpot assays ensures that observed interferon gamma secretion by iPSC-derived T cells is statistically attributable to antigen-specific activation rather than background noise. This increases confidence in functional target validation and supports robust decision-making in immunotherapy discovery pipelines.
How does independent variable isolation fit OP9/DLL1 co-culture experiments?
Isolating variables such as cytokine supplementation and antigen exposure in OP9/DLL1 co-culture allows teams to attribute T cell differentiation and function specifically to defined experimental conditions. This supports mechanistic de-risking and reproducibility in early-stage immuno-oncology research.
What do quantitative dependent variable measurements enable in T cell assays?
Quantitative measurements, such as interferon gamma secretion and T cell surface marker expression, enable objective comparison of T cell functionality and antigen specificity across experimental conditions. These outputs inform screening, optimization, and advancement decisions in cell therapy development.
Why are replication requirements critical for cross-functional T cell workflows?
Replication ensures that T cell generation, differentiation, and functional assays yield consistent results across teams and time points, supporting cross-functional collaboration and data reliability in translational research and preclinical development.
Which statistical analysis capabilities are required before ELISpot implementation?
Robust statistical analysis, including controls for background and significance testing, is essential to validate antigen-specific responses in ELISpot assays. This ensures that functional outputs are reproducible and actionable for downstream immuno-oncology workflows.
